<DOC>
	<DOCNO>NCT00005039</DOCNO>
	<brief_summary>Randomized phase II trial determine effectiveness vaccine therapy treat patient advanced adenocarcinoma prostate ( prostate cancer ) . Vaccines make person 's prostate cancer cell may make body build immune response kill tumor cell</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Advanced Adenocarcinoma Prostate ( Prostate Cancer )</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity maximum tolerate dose recombinant fowlpox prostate-specific antigen ( PSA ) vaccine patient advance adenocarcinoma prostate . II . Determine whether vaccination recombinant fowlpox-PSA vaccine associate antitumor activity patient . III . Determine efficacy prime boost regimen use recombinant fowlpox-PSA vaccine recombinant vaccinia-PSA vaccine patient . IV . Compare PSA-specific T-cell response patient treat recombinant fowlpox-PSA vaccine follow recombinant vaccinia-PSA vaccine v vaccine reverse order . OUTLINE : This randomize , open-label , multicenter , dose-escalation study recombinant fowlpox prostate-specific antigen ( PSA ) vaccine . SAFETY COHORT : The first cohort 3 patient receive vaccination recombinant fowlpox-PSA vaccine intramuscularly ( IM ) . Treatment repeat every 4 week 3 course . In absence unacceptable toxicity first cohort , second cohort 3 patient receive vaccine dose level immediately higher first cohort dose level . In presence unacceptable toxicity first cohort , second cohort 3 patient receive vaccine dose level lower first cohort dose level . The maximum tolerated dose ( MTD ) dose precede 1 6 patient experience grade 3 bad dose-limiting toxicity . Subsequent patient assign one two vaccination group base prior treatment recombinant vaccinia-PSA vaccine : GROUP A ( prior recombinant vaccinia-PSA vaccine ) : Patients randomize one two vaccination arm : ARM I : Patients receive recombinant fowlpox-PSA vaccine IM MTD safety cohort every 4 week 3 course . Patients receive recombinant vaccinia-PSA vaccine intradermally every 4 week 2 course . ARM II : Patients receive vaccine arm I reverse order . GROUP B ( prior recombinant vaccinia-PSA vaccine ) : Patients receive treatment arm I , group A . GROUPS A AND B : Patients stable respond disease 6 month completion vaccination therapy may continue treatment group arm originally assign . Treatment repeat every 6-9 month absence disease progression . Patients follow monthly 6 month every 3 month thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histologically proven adenocarcinoma prostate evidence metastatic disease include follow : Lymph node positive prostatespecific antigen ( PSA ) least 10 ng/mL Bone scan positive PSA least 10 ng/mL Prior radical prostatectomy rise PSA PSA least 2 ng/mL Prior radiotherapy PSA least 10 ng/mL Prior cryosurgery PSA least 10 ng/mL PSA criterion apply patient assign group B study previously treat vaccine trial DFCI96079 No symptomatic metastatic disease ( bony pain ) Complete HLA typing require Performance status ECOG 0 1 WBC great 2,000/mm^3 Platelet count great 100,000/mm^3 Bilirubin less 2.0 mg/dL SGPT le 4 time upper limit normal Creatinine le 4.0 mg/dL No alter immune function eczema No autoimmune disease follow : Autoimmune neutropenia , thrombocytopenia , hemolytic anemia Systemic lupus erythematosus , Sj√∂gren 's syndrome , scleroderma Myasthenia gravis Goodpasture 's syndrome Addison 's disease , Hashimoto 's thyroiditis , active Graves ' disease HIV negative No allergy untoward reaction prior vaccinia ( smallpox ) vaccination No hypersensitivity egg No prior concurrent extensive eczema skin disorder ( e.g. , extensive psoriasis , burn , impetigo , disseminate zoster ) No concurrent serious illness No active infection require antibiotic infection clear antibiotic stop least 3 day Fertile patient must use effective contraception No close contact household contact follow highrisk individual least 2 week vaccination : Children age 5 Pregnant nursing woman Individuals prior concurrent extensive eczema eczematoid skin disorder Individuals acute , chronic , exfoliative skin condition ( e.g. , atopic dermatitis , burn , impetigo , varicella zoster , severe acne , open rash wound ) Immunodeficient immunosuppressed individual ( disease therapy ) HIV infection See Disease Characteristics See Endocrine therapy Prior vaccinia ( smallpox ) immunization require No concurrent biologic therapy ( e.g. , interferon interleukin ) cancer No prior chemotherapy metastatic disease No concurrent anticancer chemotherapy No prior hormonal therapy metastatic disease Prior neoadjuvant hormonal therapy follow prostatectomy radiotherapy allow Patients previously treat recombinant vacciniaPSA vaccine may hormonal therapy since discontinue treatment ( Group B ) No concurrent hormonal therapy steroid See Disease Characteristics See Endocrine therapy No concurrent radiotherapy See Disease Characteristics See Endocrine therapy No prior splenectomy At least 3 day since prior antibiotic No concurrent immunosuppressive treatment ( e.g. , organ transplantation )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>